This site uses cookies to ensure the best viewing experience for our readers.
Exalenz Bioscience Acquired for $49M

Exalenz Bioscience Acquired for $49M

Israeli-born billionaire & biomed entrepreneur Mori Arkin sold his company for 6.10 NIS per share. Learn more on CTech!

Golan Hazani | 13:44  19.02.2020
Tel Aviv-listed Exalenz Bioscience Ltd. announced Wednesday it has accepted a deal to be acquired by an unnamed U.S. company for NIS 6.1 (approximately $1.78) per share, or a total of NIS 169 million (approximately $49.9 million), confirming an earlier report by Calcalist. The deal reflects a 70% premium on Exalenz’s share price at the beginning of trade Wednesday.

Exalenz first announced it was seeking a buyer in October. Back then, the company said it had hired the services of a leading investment bank to oversee its sale.

Mori Arkin. Photo: PR Mori Arkin. Photo: PR Mori Arkin. Photo: PR

Exalenz develops diagnostic technologies for a range of gastrointestinal and liver disorders based on an analysis of patients’ breath. The company was founded in 2006 by Israeli-born billionaire and biomed entrepreneur Mori Arkin. It is not considered one of the serial entrepreneur’s great successes, having lost 73% of its valuation over the past five years. The company, which has not yet released its annual earning reports for 2019, forecasted sales of $14 million to $15 million for the year, an 11% decrease from its initial guideline. Exalenz ended fiscal 2018 with losses of NIS 20.6 million.

The venture had already caused Arkin an $87 million loss. As he holds 74.81% of the company’s capital in his name according to TASE, the current deal will help him recuperate at least some of his investment.
share on facebook share on twitter share on linkedin share on whatsapp share on mail